BACKGROUND: A trial in African children showed that combining seasonal vaccination with the RTS,S/AS01E vaccine with seasonal malaria chemoprevention reduced the incidence of uncomplicated and severe malaria compared with either intervention given alone. Here, we report on the anti-circumsporozoite antibody response to seasonal RTS,S/AS01E vaccination in children in this trial. METHODS: Sera from a randomly selected subset of children collected before and 1 month after 3 priming doses of RTS,S/AS01E and before and 1 month after 2 seasonal booster doses were tested for anti-circumsporozoite antibodies using enzyme-linked immunosorbent assay. The association between post-vaccination antibody titer and incidence of malaria was explored. RESULTS: A strong anti-circumsporozoite antibody response to 3 priming doses of RTS,S/AS01E was seen (geometric mean titer, 368.9 enzyme-linked immunosorbent assay units/mL), but titers fell prior to the first booster dose. A strong antibody response to an annual, pre-malaria transmission season booster dose was observed, but this was lower than after the primary vaccination series and lower after the second than after the first booster dose (ratio of geometric mean rise, 0.66; 95% confidence interval [CI], .57-.77). Children whose antibody response was in the upper tercile post-vaccination had a lower incidence of malaria during the following year than children in the lowest tercile (hazard ratio, 0.43; 95% CI, .28-.66). CONCLUSIONS: Seasonal vaccination with RTS,S/AS01E induced a strong booster antibody response that was lower after the second than after the first booster dose. The diminished antibody response to the second booster dose was not associated with diminished efficacy. CLINICAL TRIALS REGISTRATION: NCT03143218.
BACKGROUND: A trial in African children showed that combining seasonal vaccination with the RTS,S/AS01E vaccine with seasonal malaria chemoprevention reduced the incidence of uncomplicated and severe malaria compared with either intervention given alone. Here, we report on the anti-circumsporozoite antibody response to seasonal RTS,S/AS01E vaccination in children in this trial. METHODS: Sera from a randomly selected subset of children collected before and 1 month after 3 priming doses of RTS,S/AS01E and before and 1 month after 2 seasonal booster doses were tested for anti-circumsporozoite antibodies using enzyme-linked immunosorbent assay. The association between post-vaccination antibody titer and incidence of malaria was explored. RESULTS: A strong anti-circumsporozoite antibody response to 3 priming doses of RTS,S/AS01E was seen (geometric mean titer, 368.9 enzyme-linked immunosorbent assay units/mL), but titers fell prior to the first booster dose. A strong antibody response to an annual, pre-malaria transmission season booster dose was observed, but this was lower than after the primary vaccination series and lower after the second than after the first booster dose (ratio of geometric mean rise, 0.66; 95% confidence interval [CI], .57-.77). Children whose antibody response was in the upper tercile post-vaccination had a lower incidence of malaria during the following year than children in the lowest tercile (hazard ratio, 0.43; 95% CI, .28-.66). CONCLUSIONS: Seasonal vaccination with RTS,S/AS01E induced a strong booster antibody response that was lower after the second than after the first booster dose. The diminished antibody response to the second booster dose was not associated with diminished efficacy. CLINICAL TRIALS REGISTRATION: NCT03143218.
Authors: E Macete; J J Aponte; C Guinovart; J Sacarlal; O Ofori-Anyinam; I Mandomando; M Espasa; C Bevilacqua; A Leach; M C Dubois; D G Heppner; L Tello; J Milman; J Cohen; F Dubovsky; N Tornieporth; R Thompson; P L Alonso Journal: Trop Med Int Health Date: 2007-01 Impact factor: 2.622
Authors: Jason A Regules; Susan B Cicatelli; Jason W Bennett; Kristopher M Paolino; Patrick S Twomey; James E Moon; April K Kathcart; Kevin D Hauns; Jack L Komisar; Aziz N Qabar; Silas A Davidson; Sheetij Dutta; Matthew E Griffith; Charles D Magee; Mariusz Wojnarski; Jeffrey R Livezey; Adrian T Kress; Paige E Waterman; Erik Jongert; Ulrike Wille-Reece; Wayne Volkmuth; Daniel Emerling; William H Robinson; Marc Lievens; Danielle Morelle; Cynthia K Lee; Bebi Yassin-Rajkumar; Richard Weltzin; Joe Cohen; Robert M Paris; Norman C Waters; Ashley J Birkett; David C Kaslow; W Ripley Ballou; Christian F Ockenhouse; Johan Vekemans Journal: J Infect Dis Date: 2016-06-13 Impact factor: 5.226
Authors: Christine Swysen; Johan Vekemans; Myriam Bruls; Sunny Oyakhirome; Chris Drakeley; Peter Kremsner; Brian Greenwood; Opokua Ofori-Anyinam; Brenda Okech; Tonya Villafana; Terrell Carter; Barbara Savarese; Adriano Duse; Andrea Reijman; Charlotte Ingram; John Frean; Bernhards Ogutu Journal: Malar J Date: 2011-08-04 Impact factor: 2.979
Authors: Ally Olotu; Frederic Clement; Erik Jongert; Johan Vekemans; Patricia Njuguna; Francis M Ndungu; Kevin Marsh; Geert Leroux-Roels; Philip Bejon Journal: PLoS One Date: 2014-12-15 Impact factor: 3.240
Authors: Seth Owusu-Agyei; Daniel Ansong; Kwaku Asante; Sandra Kwarteng Owusu; Ruth Owusu; Naana Ayiwa Wireko Brobby; David Dosoo; Alex Osei Akoto; Kingsley Osei-Kwakye; Emmanuel Asafo Adjei; Kwadwo Owusu Boahen; Justice Sylverken; George Adjei; David Sambian; Stephen Apanga; Kingsley Kayan; Johan Vekemans; Opokua Ofori-Anyinam; Amanda Leach; Marc Lievens; Marie-Ange Demoitie; Marie-Claude Dubois; Joe Cohen; W Ripley Ballou; Barbara Savarese; Daniel Chandramohan; John Owusu Gyapong; Paul Milligan; Sampson Antwi; Tsiri Agbenyega; Brian Greenwood; Jennifer Evans Journal: PLoS One Date: 2009-10-02 Impact factor: 3.240
Authors: S Moses Dennison; Matthew Reichartz; Kelly E Seaton; Sheetij Dutta; Ulrike Wille-Reece; Adrian V S Hill; Katie J Ewer; Wes Rountree; Marcella Sarzotti-Kelsoe; Daniel A Ozaki; S Munir Alam; Georgia D Tomaras Journal: J Immunol Date: 2018-07-13 Impact factor: 5.422